research Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
Omalizumab may cause hair loss.
Search
for
Sort by
Research
240-270 / 1000+ resultsresearch Gerontobiology of the Hair Follicle
research Serum Iron, Zinc, and Copper Concentration in Premature Graying of Hair
Low copper levels might cause premature graying of hair.
research Effect of cyclosporin on hair-existing area of nude mice
Cyclosporin extends hair growth in mice, but high-dose corticosteroids block this effect.
research The Comparison of In Vitro Photosensitizing Efficacy of Curcumin-Loaded Liposomes Following Photodynamic Therapy on Melanoma MUG-Mel2, Squamous Cell Carcinoma SCC-25, and Normal Keratinocyte HaCaT Cells
Liposomal curcumin improves skin cancer treatment effectiveness while sparing normal cells.
research Differentiation of human hair follicle stem cells into endothelial cells induced by vascular endothelial and basic fibroblast growth factors
Human hair follicle stem cells can become endothelial cells with certain growth factors, useful for vascular treatments.
research Human hair follicle stem cell differentiation into contractile smooth muscle cells is induced by transforming growth factor-β1 and platelet-derived growth factor BB
Human hair follicle stem cells can become smooth muscle cells using specific growth factors.
research An epistatic effect of KRT25 on SP6 is involved in curly coat in horses
The genes KRT25 and SP6 affect curly hair in horses, with KRT25 also causing hair loss. If both genes are mutated, the horse gets curly hair and hair loss. KRT25 can hide the effect of SP6.
research Cutaneous immunopathology of androgenetic alopecia
Inflammation may play a role in causing androgenetic alopecia.
research Relationship between working hours and probability to take alopecia medicine among Korean male workers: a 4-year follow-up study
Long working hours increase the risk of hair loss in Korean male workers.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
research Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
Ritlecitinib is cost-effective for severe alopecia areata in Japan.
research Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research High-Dose Vitamin D3 and Tonsillectomy as Therapeutic Management in Henoch-Schönlein Purpura Following Hepatitis B Vaccination: A Rare Case Report.
Hepatitis B vaccination can trigger HSP, and vitamin D correction and tonsillectomy can effectively manage it.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Re‐Innovation in Clinical Trial Designs Based on Precision Therapy
Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
research Is It Time to Re-Imagine Clinical Trials in Nephrology?
Metatrials could improve clinical research in nephrology by speeding up data collection and overcoming challenges like patient recruitment.
research Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
research Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications
Inconsistent safety reporting in chronic back pain trials risks patient safety and decision-making.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.